Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole K. Jeppesen, et al.
The Lancet (2021) Vol. 397, Iss. 10278, pp. 971-984
Closed Access | Times Cited: 743

Showing 1-25 of 743 citing articles:

Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 3, pp. 205-216
Open Access | Times Cited: 1663
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1127
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 6, pp. 503-515
Open Access | Times Cited: 1087
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 683
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 669
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
Kenneth Cusi, Scott Isaacs, Diana Barb, et al.
Endocrine Practice (2022) Vol. 28, Iss. 5, pp. 528-562
Open Access | Times Cited: 642
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
Domenica Rubino, Frank L. Greenway, Usman Khalid, et al.
JAMA (2022) Vol. 327, Iss. 2, pp. 138-138
Open Access | Times Cited: 575
Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 541
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Ania M. Jastreboff, Lee M. Kaplan, Juan P. Frías, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 6, pp. 514-526
Closed Access | Times Cited: 459
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John Wilding, Rachel L. Batterham, Melanie J. Davies, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 8, pp. 1553-1564
Open Access | Times Cited: 412
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
W. Timothy Garvey, Rachel L. Batterham, Meena Bhatta, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2083-2091
Open Access | Times Cited: 405
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications
Emily Brown, Hiddo J.L. Heerspink, Daniel J. Cuthbertson, et al.
The Lancet (2021) Vol. 398, Iss. 10296, pp. 262-276
Open Access | Times Cited: 380
Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association
Joshua J. Joseph, Prakash Deedwania, Tushar Acharya, et al.
Circulation (2022) Vol. 145, Iss. 9
Open Access | Times Cited: 370
Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation
Ildiko Lingvay, Priya Sumithran, Ricardo V. Cohen, et al.
The Lancet (2021) Vol. 399, Iss. 10322, pp. 394-405
Closed Access | Times Cited: 365
Contemporary medical, device, and surgical therapies for obesity in adults
Carolina M. Perdomo, Ricardo V. Cohen, Priya Sumithran, et al.
The Lancet (2023) Vol. 401, Iss. 10382, pp. 1116-1130
Closed Access | Times Cited: 345
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 315
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
W. Timothy Garvey, Juan P. Frías, Ania M. Jastreboff, et al.
The Lancet (2023) Vol. 402, Iss. 10402, pp. 613-626
Open Access | Times Cited: 310
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Katherine R. Tuttle, Rajiv Agarwal, Charles E. Alpers, et al.
Kidney International (2022) Vol. 102, Iss. 2, pp. 248-260
Open Access | Times Cited: 292
GLP-1 physiology informs the pharmacotherapy of obesity
Daniel J. Drucker
Molecular Metabolism (2021) Vol. 57, pp. 101351-101351
Open Access | Times Cited: 273
5. Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes:Standards of Care in Diabetes—2023
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, et al.
Diabetes Care (2022) Vol. 46, Iss. Supplement_1, pp. S68-S96
Open Access | Times Cited: 270
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
John W. McEvoy, Cian P. McCarthy, Rosa María Bruno, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 267
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 249
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi, Yang Wang, Qiukui Hao, et al.
The Lancet (2021) Vol. 399, Iss. 10321, pp. 259-269
Closed Access | Times Cited: 238
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 231
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
Lone B Enebo, Kasper K. Berthelsen, Martin Kankam, et al.
The Lancet (2021) Vol. 397, Iss. 10286, pp. 1736-1748
Closed Access | Times Cited: 218
Page 1 - Next Page

Scroll to top